-
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Wednesday, April 17, 2024 - 8:42am | 1019DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings The Drug Enforcement Administration (DEA) is revisiting its stance on the classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC)....
-
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
Tuesday, March 12, 2024 - 1:13pm | 853Welcome to a new episode of our Benzinga Psychedelics Podcast. We are joined herein by executives of Clearmind Medicine (NASDAQ:CMND), a biotech company developing a proprietary, psychoactive yet non-hallucinogenic treatment for a diverse array of addictive behaviors, with Alcohol Use Disorder (aka...
-
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Thursday, February 29, 2024 - 12:04pm | 752Welcome to a new episode of our Benzinga Psychedelics Podcast, this time joined by business trendspotter and "psychedelics concierge" Zappy Zapolin. He has served in a range of positions, from advisor to psychedelic companies like KetaMD – acquired by Braxia Scientific (OTC:BRAXF) and chief...
-
Podcast: International Cannabis And Psychedelics Co. Is Working 'Hand In Hand' With FDA To Forge New Therapy Frontiers
Thursday, January 25, 2024 - 2:44pm | 498Welcome to the inaugural episode of the Benzinga Psychedelics Podcast. In this exciting kickoff, we're joined by Joel Latham, experienced biotech industry leader and CEO of Incannex Healthcare (NASDAQ:IXHL). Dive into our engaging conversation as we explore Incannex's strategic expansion into...